Caliway Biopharmaceuticals (6919.TWO) Earnings Analysis
Caliway Biopharmaceuticals (6919.TWO) next reports earnings on 2026-08-07, consensus EPS 2.91 TWD. Last quarter (2026-04-10) it beat with EPS -0.22 TWD vs -0.22 TWD est (0%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -554.33.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 6919.TWO next report earnings?
| Next earnings date | 2026-08-07 |
|---|---|
| Consensus EPS estimate | 2.91 TWD |
| Revenue estimate | 6.01B |
6919.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-10 | -0.22 TWD | -0.22 TWD | 0% | Beat |
| 2025-11-07 | -0.005 TWD | -0.19 TWD | +97.4% | Beat |
| 2025-08-08 | -0.16387 TWD | -0.13622 TWD | -20.3% | Miss |
| 2024-09-30 | -0.99 TWD | n/a | n/a | n/a |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
6919.TWO valuation and analyst view
| Trailing P/E | -554.33 |
|---|---|
| Trailing EPS | -0.1826 TWD |
| Price / book | 16.63 |
| Dividend yield | 0.00% |
| Market cap | 15.96B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Caliway Biopharmaceuticals (6919.TWO)'s next earnings date?
Caliway Biopharmaceuticals is next scheduled to report on 2026-08-07, with a consensus EPS estimate of 2.91 TWD and revenue estimate of 6.01B.
Did 6919.TWO beat earnings last quarter?
In its 2026-04-10 report, 6919.TWO posted EPS of -0.22 TWD versus a -0.22 TWD estimate — a beat of 0%.
What is 6919.TWO's earnings track record?
Over the last 3 reported quarters with consensus data, 6919.TWO beat estimates 2 times (67%).
What is 6919.TWO's current P/E ratio and EPS?
6919.TWO trades at a trailing P/E of -554.33 on trailing EPS of -0.18259841193422846 TWD.
What do analysts rate 6919.TWO?
6919.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.